TY - JOUR
T1 - Influence of varying quantitative fecal immunochemical test positivity thresholds on colorectal cancer detection
T2 - A community-based cohort study
AU - Selby, Kevin
AU - Jensen, Christopher D.
AU - Lee, Jeffrey K.
AU - Doubeni, Chyke A.
AU - Schottinger, Joanne E.
AU - Zhao, Wei K.
AU - Chubak, Jessica
AU - Halm, Ethan
AU - Ghai, Nirupa R.
AU - Contreras, Richard
AU - Skinner, Celette
AU - Kamineni, Aruna
AU - Levin, Theodore R.
AU - Corley, Douglas A.
N1 - Funding Information:
Disclosures: Dr. Selby reports grants from the Swiss Cancer Research Foundation during the conduct of the study. Drs. Jensen and Levin report grants from NCI during the conduct of the study. Dr. Doubeni is a member of the U.S. Preventive Services Task Force and a topic author for UpToDate. Dr. Corley reports grants from the National Institutes of Health during the conduct of the study. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms .do?msNum=M18-0244.
Funding Information:
The authors thank Peter Bacchetti and Robert Hiatt for their detailed feedback during manuscript preparation. National Cancer Institute. This study was conducted within the NCI funded (grant U54 CA163262) PROSPR II consortium, which conducts multisite, coordinated, transdisciplinary research to evaluate and improve cancer screening processes. It was also funded by grants K07 CA212057 from the NCI and BIL KFS-3720-08-2015 from the Swiss Cancer Research Foundation.
Funding Information:
Grant Support: This study was conducted within the NCI-funded (grant U54 CA163262) PROSPR II consortium, which conducts multisite, coordinated, transdisciplinary research to evaluate and improve cancer screening processes. It was also funded by grants K07 CA212057 from the NCI and BIL KFS-3720-08-2015 from the Swiss Cancer Research Foundation.
Publisher Copyright:
© 2018 American College of Physicians.
PY - 2018/10/2
Y1 - 2018/10/2
N2 - Background: The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex. Objective: To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative hemoglobin positivity thresholds in a large, population-based, screening program. Design: Retrospective cohort study. Setting: Kaiser Permanente Northern and Southern California. Participants: Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years. Measurements: FIT programmatic sensitivity for CRC and number of positive test results per cancer case detected, overall and by age and sex. Results: Of 640 859 persons who completed a baseline FIT and were followed for 2 years, 481 817 (75%) had at least 1 additional FIT and 1245 (0.19%) received a CRC diagnosis. Cancer detection (programmatic sensitivity) increased at lower positivity thresholds, from 822 in 1245 (66.0%) at 30 μg/g to 925 (74.3%) at 20 μg/g and 987 (79.3%) at 10 μg/g; the number of positive test results per cancer case detected increased from 43 at 30 μg/g to 52 at 20 μg/g and 85 at 10 μg/g. Reducing the positivity threshold from 20 to 15 μg/g would detect 3% more cancer cases and require 23% more colonoscopies. At the conventional FIT threshold of 20 μg/g, programmatic sensitivity decreased with increasing age (79.0%, 73.4%, and 68.9% for ages 50 to 59, 60 to 69, and 70 to 75 years, respectively; P = 0.009) and was higher in men than women (77.0% vs. 70.6%; P = 0.011). Limitation: Information on advanced adenoma was lacking. Conclusion: Increased cancer detection at lower positivity thresholds is counterbalanced by substantial increases in positive tests. Tailored thresholds may provide screening benefits that are more equal among different demographic groups, depending on local resources.
AB - Background: The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex. Objective: To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative hemoglobin positivity thresholds in a large, population-based, screening program. Design: Retrospective cohort study. Setting: Kaiser Permanente Northern and Southern California. Participants: Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years. Measurements: FIT programmatic sensitivity for CRC and number of positive test results per cancer case detected, overall and by age and sex. Results: Of 640 859 persons who completed a baseline FIT and were followed for 2 years, 481 817 (75%) had at least 1 additional FIT and 1245 (0.19%) received a CRC diagnosis. Cancer detection (programmatic sensitivity) increased at lower positivity thresholds, from 822 in 1245 (66.0%) at 30 μg/g to 925 (74.3%) at 20 μg/g and 987 (79.3%) at 10 μg/g; the number of positive test results per cancer case detected increased from 43 at 30 μg/g to 52 at 20 μg/g and 85 at 10 μg/g. Reducing the positivity threshold from 20 to 15 μg/g would detect 3% more cancer cases and require 23% more colonoscopies. At the conventional FIT threshold of 20 μg/g, programmatic sensitivity decreased with increasing age (79.0%, 73.4%, and 68.9% for ages 50 to 59, 60 to 69, and 70 to 75 years, respectively; P = 0.009) and was higher in men than women (77.0% vs. 70.6%; P = 0.011). Limitation: Information on advanced adenoma was lacking. Conclusion: Increased cancer detection at lower positivity thresholds is counterbalanced by substantial increases in positive tests. Tailored thresholds may provide screening benefits that are more equal among different demographic groups, depending on local resources.
UR - http://www.scopus.com/inward/record.url?scp=85054230150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054230150&partnerID=8YFLogxK
U2 - 10.7326/M18-0244
DO - 10.7326/M18-0244
M3 - Article
C2 - 30242328
AN - SCOPUS:85054230150
SN - 0003-4819
VL - 169
SP - 439
EP - 447
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 7
ER -